Mucocutaneous leishmaniasis
diseaseOn this page
Also known as American cutaneous leishmaniasisAmerican mucocutaneous leishmaniasiscutaneous leishmaniasis, Americanmucocutaneous leishmaniasis, (American)
Summary
Mucocutaneous leishmaniasis (MONDO:0005859) is a disease and 9 clinical trials. Top therapeutic interventions include miltefosine, paromomycin, and tofacitinib. A subtype of leishmaniasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | mucocutaneous leishmaniasis |
| Mondo ID | MONDO:0005859 |
| EFO | EFO:0007379 |
| MeSH | D007897 |
| DOID | DOID:9155 |
| ICD-10-CM | B55.2 |
| ICD-11 | 1942095878 |
| NCIT | C34769 |
| UMLS | C1328252 |
| MedGen | 233065 |
| GARD | 0024244 |
| Is cancer (heuristic) | no |
Also known as: American cutaneous leishmaniasis · American mucocutaneous leishmaniasis · cutaneous leishmaniasis, American · mucocutaneous leishmaniasis, (American)
Disease family
This is a subtype of leishmaniasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › leishmaniasis › mucocutaneous leishmaniasis
Related subtypes (2): visceral leishmaniasis, cutaneous leishmaniasis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Miltefosine | Approved (phase 4) |
| ANTIMONY CATION (5+) | Phase 3 (in late-stage trials) |
| Amphotericin B | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Meglumine, Meglumine Antimonate.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 3 |
| Not specified | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01301937 | PHASE2/PHASE3 | UNKNOWN | Low Antimonial Dosage in American Mucosal Leishmaniasis |
| NCT03829917 | PHASE2/PHASE3 | COMPLETED | Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis |
| NCT06011343 | PHASE2/PHASE3 | UNKNOWN | Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis |
| NCT06000514 | PHASE1/PHASE2 | COMPLETED | Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. |
| NCT06449040 | PHASE1/PHASE2 | COMPLETED | Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly |
| NCT07149753 | PHASE1 | NOT_YET_RECRUITING | Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis |
| NCT02429518 | Not specified | COMPLETED | Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis |
| NCT02431429 | Not specified | COMPLETED | Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis |
| NCT05533736 | Not specified | COMPLETED | Feasibility and Usability of Mobile Applications for Monitoring Cutaneous Leishmaniasis Treatment in Colombia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MILTEFOSINE | 4 | 3 |
| PAROMOMYCIN | 4 | 3 |
| TOFACITINIB | 4 | 3 |
| MEGLUMINE ANTIMONATE | 3 | 1 |
| CHEMBL4537559 | 0 | 1 |
| CHEMBL454494 | 0 | 1 |